Survival outcomes in patients aged 75 years and over with peritoneal colorectal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): multicenter study of the Spanish Group of Peritoneal Cancer Surgery (GECOP).
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Chemotherapy, Cancer, Regional Perfusion
/ mortality
Colorectal Neoplasms
/ mortality
Combined Modality Therapy
Cytoreduction Surgical Procedures
/ mortality
Female
Follow-Up Studies
Humans
Hyperthermia, Induced
/ mortality
Male
Peritoneal Neoplasms
/ mortality
Prognosis
Retrospective Studies
Spain
Survival Rate
Colorectal carcinomatosis
Elderly
HIPEC
Morbidity
Survival
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
26
03
2019
accepted:
19
04
2019
pubmed:
3
5
2019
medline:
2
10
2020
entrez:
4
5
2019
Statut:
ppublish
Résumé
The attitude toward cytoreductive surgery with HIPEC in peritoneal carcinomatosis from colorectal cancer is unclear. The aim of this study is to report the perioperative outcomes after cytoreductive surgery with HIPEC in patients ≥ 75 years. This retrospective multicenter study collected the data the Spanish Group of Peritoneal Cancer Surgery. Thirty-six patients with peritoneal carcinomatosis from colorectal cancer met the selection criteria for the study. Morbidity, mortality, disease-free and overall survival were analyzed. Morbidity (grade III-IV) was 17% and 2 patients died of complications related to the procedure (5.4%). Median disease-free survival (DFS) was 16 months. DFS at 1 and 3 years was 81% and 42%, respectively. Overall survival at 1 and 3 years was 96% and 75%. In the univariate analysis, preoperative comorbidities (p = 0.01), liver metastases (p = 0.02), blood transfusion (p = 0.001) and postoperative complications (p = 0.001); and in the multivariate analysis, perioperative blood transfusion (OR 2.56, 95% CI 1.95-6.24, p = 0.03) and postoperative complications (OR 3.25, 95% CI 2.35-7.56, p = 0.02) were associated with a lower overall survival. Age is not an absolute contraindication to perform cytoreduction surgery with HIPEC in highly selected elderly patients with colorectal peritoneal carcinomatosis.
Sections du résumé
BACKGROUND
BACKGROUND
The attitude toward cytoreductive surgery with HIPEC in peritoneal carcinomatosis from colorectal cancer is unclear. The aim of this study is to report the perioperative outcomes after cytoreductive surgery with HIPEC in patients ≥ 75 years.
METHODS
METHODS
This retrospective multicenter study collected the data the Spanish Group of Peritoneal Cancer Surgery. Thirty-six patients with peritoneal carcinomatosis from colorectal cancer met the selection criteria for the study. Morbidity, mortality, disease-free and overall survival were analyzed.
RESULTS
RESULTS
Morbidity (grade III-IV) was 17% and 2 patients died of complications related to the procedure (5.4%). Median disease-free survival (DFS) was 16 months. DFS at 1 and 3 years was 81% and 42%, respectively. Overall survival at 1 and 3 years was 96% and 75%. In the univariate analysis, preoperative comorbidities (p = 0.01), liver metastases (p = 0.02), blood transfusion (p = 0.001) and postoperative complications (p = 0.001); and in the multivariate analysis, perioperative blood transfusion (OR 2.56, 95% CI 1.95-6.24, p = 0.03) and postoperative complications (OR 3.25, 95% CI 2.35-7.56, p = 0.02) were associated with a lower overall survival.
CONCLUSIONS
CONCLUSIONS
Age is not an absolute contraindication to perform cytoreduction surgery with HIPEC in highly selected elderly patients with colorectal peritoneal carcinomatosis.
Identifiants
pubmed: 31049819
doi: 10.1007/s12094-019-02124-9
pii: 10.1007/s12094-019-02124-9
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
130-136Références
Int J Surg Oncol. 2014;2014:987475
pubmed: 24809147
J Clin Oncol. 2004 Aug 15;22(16):3284-92
pubmed: 15310771
Ann Surg. 2011 May;253(5):890-9
pubmed: 21394013
J Clin Oncol. 2004 Jan 15;22(2):229-37
pubmed: 14657227
J Clin Oncol. 2003 Oct 15;21(20):3737-43
pubmed: 14551293
Ann Surg Oncol. 2013 Oct;20(11):3497-503
pubmed: 23780382
J Trauma. 2003 May;54(5):908-14
pubmed: 12777903
Surg Oncol. 2016 Dec;25(4):378-384
pubmed: 27916169
Ann Surg Oncol. 2014 Dec;21(13):4195-201
pubmed: 24854493
Eur J Cancer. 2019 Mar;109:70-83
pubmed: 30690295
J Clin Oncol. 2008 Apr 20;26(12):2013-9
pubmed: 18421054
Eur J Surg Oncol. 2009 Nov;35(11):1186-91
pubmed: 19356887
Ann Surg. 2012 Aug;256(2):235-44
pubmed: 22791100
Surg Oncol. 2016 Jun;25(2):111-6
pubmed: 27312037
Ann Surg Oncol. 2015 Aug;22(8):2656-62
pubmed: 25515200
In Vivo. 2011 Jul-Aug;25(4):687-90
pubmed: 21709015
Ann Surg Oncol. 2004 May;11(5):518-21
pubmed: 15123461
Lancet Oncol. 2014 Sep;15(10):1065-75
pubmed: 25088940
J Clin Oncol. 2006 Aug 20;24(24):4011-9
pubmed: 16921055
Anticancer Res. 2003 May-Jun;23(3C):3019-27
pubmed: 12926156
Ann Surg Oncol. 2008 Sep;15(9):2426-32
pubmed: 18521686
J Surg Oncol. 2012 Feb;105(2):113-8
pubmed: 21780124
Surg Oncol. 2013 Sep;22(3):184-9
pubmed: 23827047
J Surg Oncol. 2014 Dec;110(7):779-85
pubmed: 25088304
J Clin Oncol. 2011 May 20;29(15):2011-9
pubmed: 21502544
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Gynecol Oncol. 2007 Jul;106(1):193-200
pubmed: 17466362
Ann Surg. 2010 Jan;251(1):101-6
pubmed: 19838105
Br J Cancer. 2004 Jan 26;90(2):403-7
pubmed: 14735184
J Surg Oncol. 2003 Jul;83(3):147-53
pubmed: 12827682